메뉴 건너뛰기




Volumn 5, Issue 1, 2013, Pages 42-50

Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer: An overview

Author keywords

Anthracycline; Chemotherapy; Cytotoxic agents; Drug resistance; MBC; Metastatic breast cancer; Pretreated; Systemic cytotoxic therapy; Taxane

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ERIBULIN; ETIRINOTECAN PEGOL; GEMCITABINE; INIPARIB; IRINOTECAN; IXABEPILONE; LAPATINIB; MITOMYCIN; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PLATINUM COMPLEX; TAXANE DERIVATIVE; VINBLASTINE;

EID: 84873455707     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-012-0097-1     Document Type: Article
Times cited : (57)

References (56)
  • 3
    • 76749156249 scopus 로고    scopus 로고
    • Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study
    • 10.1200/JCO.2008.20.5013 1:CAS:528:DC%2BD1MXhtlCns77I Demonstrated cardiac safety for pegylated liposomal doxorubicin after previous exposure to adjuvant anthracycline therapy
    • Sparano JA, Makhson AN, Semiglazov VF. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009;27:4522-9. Demonstrated cardiac safety for pegylated liposomal doxorubicin after previous exposure to adjuvant anthracycline therapy.
    • (2009) Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology , vol.27 , pp. 4522-4529
    • Sparano, J.A.1    Makhson, A.N.2    Semiglazov, V.F.3
  • 5
    • 0037441856 scopus 로고    scopus 로고
    • Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193)
    • DOI 10.1200/JCO.2003.08.013
    • Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21:588-92. (Pubitemid 46621890)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.4 , pp. 588-592
    • Sledge, G.W.1    Neuberg, D.2    Bernardo, P.3    Ingle, J.N.4    Martino, S.5    Rowinsky, E.K.6    Wood, W.C.7
  • 7
    • 0021070147 scopus 로고
    • Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study
    • 6365209 10.1007/BF01807589 1:STN:280:DyaL2c7ivV2lsA%3D%3D
    • Kardinal CG, Perry MC, Weinberg V, Wood W, Ginsberg S, Raju RN. Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study. Breast Cancer Res Treat. 1983;3:365-71.
    • (1983) Breast Cancer Res Treat , vol.3 , pp. 365-371
    • Kardinal, C.G.1    Perry, M.C.2    Weinberg, V.3    Wood, W.4    Ginsberg, S.5    Raju, R.N.6
  • 8
    • 84863707351 scopus 로고    scopus 로고
    • Cancer treatment and survivorship statistics, 2012
    • 22700443 10.3322/caac.21149
    • Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-41.
    • (2012) CA Cancer J Clin , vol.62 , pp. 220-241
    • Siegel, R.1    Desantis, C.2    Virgo, K.3
  • 9
    • 0036307010 scopus 로고    scopus 로고
    • Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades?
    • DOI 10.1093/annonc/mdf101
    • Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, Piccart MJ. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol. 2002;13:197-207. (Pubitemid 34704970)
    • (2002) Annals of Oncology , vol.13 , Issue.2 , pp. 197-207
    • Cardoso, F.1    Di Leo, A.2    Lohrisch, C.3    Bernard, C.4    Ferreira, F.5    Piccart, M.J.6
  • 10
    • 31444447160 scopus 로고    scopus 로고
    • Extending survival with chemotherapy in metastatic breast cancer
    • DOI 10.1634/theoncologist.10-90003-20
    • O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3:20-9. (Pubitemid 43152727)
    • (2005) Oncologist , vol.10 , Issue.SUPPL.. 3 , pp. 20-29
    • O'Shaughnessy, J.1
  • 13
    • 79952487463 scopus 로고    scopus 로고
    • Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
    • 21376385 10.1016/S0140-6736(11)60070-6 1:CAS:528:DC%2BC3MXjtFWgs7c%3D Demonstrated that eribulin improved survival compared with physician's choice of another monotherapy regimen for patients with extensively pretreated metastatic breast cancer
    • •• Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914-23. Demonstrated that eribulin improved survival compared with physician's choice of another monotherapy regimen for patients with extensively pretreated metastatic breast cancer.
    • (2011) Lancet , vol.377 , pp. 914-923
    • Cortes, J.1    O'Shaughnessy, J.2    Loesch, D.3
  • 15
    • 0346847742 scopus 로고    scopus 로고
    • Is Breast Cancer Survival Improving? Trends in Survival for Patients with Recurrent Breast Cancer Diagnosed from 1974 through 2000
    • DOI 10.1002/cncr.11859
    • Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100:44-52. (Pubitemid 37553538)
    • (2004) Cancer , vol.100 , Issue.1 , pp. 44-52
    • Giordano, S.H.1    Buzdar, A.U.2    Smith, T.L.3    Kau, S.-W.4    Yang, Y.5    Hortobagyi, G.N.6
  • 18
    • 84874672704 scopus 로고    scopus 로고
    • Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years
    • Tevaarwerk AJ, Gray RJ, Schneider BP, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years. Cancer 2012
    • (2012) Cancer
    • Tevaarwerk, A.J.1    Gray, R.J.2    Schneider, B.P.3
  • 20
    • 77954752064 scopus 로고    scopus 로고
    • Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    • 10.1200/JCO.2009.24.4244 1:CAS:528:DC%2BC3cXhtVajur3E Phase III trial which showed that the ixabepilone-capecitabine combination improved response and progression-free survival compared with capecitabine alone for anthracycline and taxane-pretreated breast cancer; the combination did not improve survival
    • •• Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28:3256-63. Phase III trial which showed that the ixabepilone-capecitabine combination improved response and progression-free survival compared with capecitabine alone for anthracycline and taxane-pretreated breast cancer; the combination did not improve survival.
    • (2010) Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology , vol.28 , pp. 3256-3263
    • Sparano, J.A.1    Vrdoljak, E.2    Rixe, O.3
  • 21
    • 0033953330 scopus 로고    scopus 로고
    • A unified definition of clinical anthracycline resistance breast cancer
    • Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer. 2000;82:529-34. Proposed definitions for anthracycine and taxane pretreatment versus resistance. (Pubitemid 30085185)
    • (2000) British Journal of Cancer , vol.82 , Issue.3 , pp. 529-534
    • Pivot, X.1    Asmar, L.2    Buzdar, A.U.3    Valero, V.4    Hortobagyi, G.5
  • 23
    • 80052908255 scopus 로고    scopus 로고
    • Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy
    • 10.1159/000327515
    • Guo X, Loibl S, Untch M, et al. Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy. Breast Care (Basel). 2011;6:279-83.
    • (2011) Breast Care (Basel) , vol.6 , pp. 279-283
    • Guo, X.1    Loibl, S.2    Untch, M.3
  • 24
    • 13644254794 scopus 로고    scopus 로고
    • Molecular mechanisms of drug resistance
    • DOI 10.1002/path.1706
    • Longley DB, Johnston PG. Molecular mechanisms of drug resistance. The Journal of pathology. 2005;205:275-92. (Pubitemid 40227997)
    • (2005) Journal of Pathology , vol.205 , Issue.2 , pp. 275-292
    • Longley, D.B.1    Johnston, P.G.2
  • 25
    • 36049029703 scopus 로고    scopus 로고
    • The role of efflux pumps in drug-resistant metastatic breast cancer: New insights and treatment strategies
    • Fojo T, Coley HM. The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. Clin Breast Cancer. 2007;7:749-56. (Pubitemid 350086119)
    • (2007) Clinical Breast Cancer , vol.7 , Issue.10 , pp. 749-756
    • Fojo, T.1    Coley, H.M.2
  • 27
    • 0035476911 scopus 로고    scopus 로고
    • Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
    • DOI 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A
    • •• Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759-68. Demonstrated efficacy of capecitabine monotherapy for anthracycline and taxane-pretreated metastatic breast cancer. (Pubitemid 32952493)
    • (2001) Cancer , vol.92 , Issue.7 , pp. 1759-1768
    • Blum, J.L.1    Dieras, V.2    Russo, P.M.L.3    Horton, J.4    Rutman, O.5    Buzdar, A.6    Osterwalder, B.7
  • 29
    • 42949171085 scopus 로고    scopus 로고
    • Phase i study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer
    • 18398145 10.1200/JCO.2007.13.8388 1:CAS:528:DC%2BD1cXmsFemsLc%3D
    • Traina TA, Theodoulou M, Feigin K, et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol. 2008;26:1797-802.
    • (2008) J Clin Oncol , vol.26 , pp. 1797-1802
    • Traina, T.A.1    Theodoulou, M.2    Feigin, K.3
  • 32
    • 3042701597 scopus 로고    scopus 로고
    • Epothilones: Mechanism of action and biologic activity
    • DOI 10.1200/JCO.2004.12.001
    • Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol. 2004;22:2015-25. (Pubitemid 41095195)
    • (2004) Journal of Clinical Oncology , vol.22 , Issue.10 , pp. 2015-2025
    • Goodin, S.1    Kane, M.P.2    Rubin, E.H.3
  • 34
    • 79251530503 scopus 로고    scopus 로고
    • Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: A pooled analysis by performance status of efficacy and safety data from 2 phase III studies
    • 21128114 10.1007/s10549-010-1251-y 1:CAS:528:DC%2BC3MXhtVelsLk%3D Pooled analysis of 2 phase III trials indicating a survival benefit of the ixabepilone-capecitabine combination compared with capecitabine alone for patients with a Karnofsky performance status of 70-80, but not 90-100
    • Roche H, Conte P, Perez EA, et al. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: A pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast cancer research and treatment. 2011;125:755-65. Pooled analysis of 2 phase III trials indicating a survival benefit of the ixabepilone-capecitabine combination compared with capecitabine alone for patients with a Karnofsky performance status of 70-80, but not 90-100.
    • (2011) Breast Cancer Research and Treatment , vol.125 , pp. 755-765
    • Roche, H.1    Conte, P.2    Perez, E.A.3
  • 35
    • 78751525051 scopus 로고    scopus 로고
    • Eribulin induces irreversible mitotic blockade: Implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions
    • 21127197 10.1158/0008-5472.CAN-10-1874 1:CAS:528:DC%2BC3MXlsFKlsA%3D%3D
    • Towle MJ, Salvato KA, Wels BF, et al. Eribulin induces irreversible mitotic blockade: Implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011;71:496-505.
    • (2011) Cancer Res , vol.71 , pp. 496-505
    • Towle, M.J.1    Salvato, K.A.2    Wels, B.F.3
  • 36
    • 67649908927 scopus 로고    scopus 로고
    • Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    • 19349550 10.1200/JCO.2008.17.7618 1:CAS:528:DC%2BD1MXoslyis74%3D
    • Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;27:2954-61.
    • (2009) J Clin Oncol , vol.27 , pp. 2954-2961
    • Vahdat, L.T.1    Pruitt, B.2    Fabian, C.J.3
  • 37
    • 77957594393 scopus 로고    scopus 로고
    • Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
    • 20679609 10.1200/JCO.2009.25.8467 1:CAS:528:DC%2BC3cXht1eqsbzM
    • Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28:3922-8.
    • (2010) J Clin Oncol , vol.28 , pp. 3922-3928
    • Cortes, J.1    Vahdat, L.2    Blum, J.L.3
  • 38
    • 84861733607 scopus 로고    scopus 로고
    • A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
    • 21989327 10.1093/annonc/mdr444 1:STN:280:DC%2BC38zmsVSrtw%3D%3D
    • Aogi K, Iwata H, Masuda N, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012;23:1441-8.
    • (2012) Ann Oncol , vol.23 , pp. 1441-1448
    • Aogi, K.1    Iwata, H.2    Masuda, N.3
  • 39
    • 84873470069 scopus 로고    scopus 로고
    • Eribulin301. http://www.eisai.com/news/enews201244pdf.pdf. 2012
    • (2012) Eribulin301
  • 40
    • 0028799108 scopus 로고
    • Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
    • 7481842 1:CAS:528:DyaK2MXpsFGntbY%3D
    • Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22:3-10.
    • (1995) Semin Oncol , vol.22 , pp. 3-10
    • Plunkett, W.1    Huang, P.2    Xu, Y.Z.3    Heinemann, V.4    Grunewald, R.5    Gandhi, V.6
  • 42
    • 0032947768 scopus 로고    scopus 로고
    • Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
    • Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17:409-22. (Pubitemid 29022420)
    • (1999) Journal of Clinical Oncology , vol.17 , Issue.1 , pp. 409-422
    • Go, R.S.1    Adjei, A.A.2
  • 43
    • 78649663174 scopus 로고    scopus 로고
    • BRCA mutations in the management of breast cancer: The state of the art
    • 20956982 10.1038/nrclinonc.2010.166 1:CAS:528:DC%2BC3cXhsVygtr3E
    • Narod SA. BRCA mutations in the management of breast cancer: The state of the art. Nat Rev Clin Oncol. 2010;7:702-7.
    • (2010) Nat Rev Clin Oncol , vol.7 , pp. 702-707
    • Narod, S.A.1
  • 44
    • 1242329822 scopus 로고    scopus 로고
    • Platinum-based chemotherapy in metastatic breast cancer: Current status
    • DOI 10.1016/S0305-7372(03)00139-7
    • Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: Current status. Cancer Treat Rev. 2004;30:53-81. (Pubitemid 38240088)
    • (2004) Cancer Treatment Reviews , vol.30 , Issue.1 , pp. 53-81
    • Decatris, M.P.1    Sundar, S.2    O'Byrne, K.J.3
  • 46
    • 78751610848 scopus 로고    scopus 로고
    • Iniparib plus chemotherapy in metastatic triple-negative breast cancer
    • 21208101 10.1056/NEJMoa1011418
    • O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205-14.
    • (2011) N Engl J Med , vol.364 , pp. 205-214
    • O'Shaughnessy, J.1    Osborne, C.2    Pippen, J.E.3
  • 47
    • 84859202634 scopus 로고    scopus 로고
    • Drug candidates derailed in case of mistaken identity
    • 22460874 10.1038/483519a 1:CAS:528:DC%2BC38Xks12huro%3D
    • Ledford H. Drug candidates derailed in case of mistaken identity. Nature. 2012;483:519.
    • (2012) Nature , vol.483 , pp. 519
    • Ledford, H.1
  • 50
    • 77749264641 scopus 로고    scopus 로고
    • 28th Annual JPMorgan Healthcare Conference - Exelixis and Nektar Therapeutics
    • 20191424
    • Gale S, Croasdell G. 28th Annual JPMorgan Healthcare Conference - Exelixis and Nektar Therapeutics. IDrugs. 2010;13:139-41.
    • (2010) IDrugs , vol.13 , pp. 139-141
    • Gale, S.1    Croasdell, G.2
  • 51
    • 0000631893 scopus 로고
    • Negative Staining of Phospholipids and Their Structural Modification by Surface-Active Agents as Observed in the Electron Microscope
    • 14187392 10.1016/S0022-2836(64)80115-7 1:CAS:528:DyaF2cXktlers70%3D
    • Bangham AD, Horne RW. Negative Staining of Phospholipids and Their Structural Modification by Surface-Active Agents as Observed in the Electron Microscope. J Mol Biol. 1964;8:660-8.
    • (1964) J Mol Biol , vol.8 , pp. 660-668
    • Bangham, A.D.1    Horne, R.W.2
  • 52
    • 0027299669 scopus 로고
    • Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): Comparison with doxorubicin and empty liposomes in mice and dogs
    • Kanter PM, Bullard GA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo. 1993;7:85-95. (Pubitemid 23156481)
    • (1993) In Vivo , vol.7 , Issue.1 , pp. 85-95
    • Kanter, P.M.1    Bullard, G.A.2    Pilkiewicz, F.G.3    Mayer, L.D.4    Cullis, P.R.5    Pavelic, Z.P.6
  • 54
    • 0037681850 scopus 로고    scopus 로고
    • Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies
    • DOI 10.2165/00003088-200342050-00002
    • Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419-36. (Pubitemid 36649037)
    • (2003) Clinical Pharmacokinetics , vol.42 , Issue.5 , pp. 419-436
    • Gabizon, A.1    Shmeeda, H.2    Barenholz, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.